XML 107 R76.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Information    
Revenue $ 5,000 $ 50,000
Research and development expenses (139,139) (60,033)
General and administrative (29,749) (17,114)
Stock-based compensation (10,821) (3,495)
Net loss to common stockholders (156,988) (37,124)
Single Reportable Segment    
Segment Information    
Revenue 5,000 50,000
General and administrative 22,995 15,218
Stock-based compensation 10,821 3,495
Other segment items (6,901) 9,977
Net loss to common stockholders (156,988) (37,124)
Single Reportable Segment | Obexelimab    
Segment Information    
Research and development expenses 94,563 25,446
Single Reportable Segment | Other programs (ZB002 & ZB004)    
Segment Information    
Research and development expenses 2,115 6,242
Single Reportable Segment | Partnered regional programs (ZB001 & ZB005)    
Segment Information    
Research and development expenses 6,737 6,738
Single Reportable Segment | Unallocated    
Segment Information    
Research and development expenses $ 31,658 $ 20,008